Endo Health Solutions
|Traded as||NASDAQ: ENDP|
|Headquarters||Chadds Ford, Pennsylvania|
Endo Health Solutions Inc. is an American pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called Endo Pharmaceuticals Inc. On 23rd May 2012, Endo's shareholders approved a resolution to change the company's name to Endo Health Solutions Inc..
Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQ: ENDP). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt.
Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.
Endo contracts some production and quality control testing from Novartis, at the Novartis manufacturing facility in Lincoln, Nebraska. Prior to its December 2011 shutdown, this particular Novartis manufacturing facility made all Excedrin distributed in the United States.
- Chief executive officer: David P. Holveck (as of April 2008)
- Chief financial officer: Charles A. Rowland Jr. (Resigned Sept 2008)
- The company's sales force numbers 690
- Amantadine (Symmetrel)
- Carbidopa with levodopa (Carbidopa/Levodopa USP)
- Frovatriptan (Frova)
- Hydrocodone with acetaminophen (Zydone)
- Hydrocodone with homatropine (Hycodan)
- Lidocaine (Lidoderm)
- Lidocaine with tetracaine (Synera)
- Molindone (Moban)
- Oxycodone with acetaminophen (Percocet, Endocet)
- Oxycodone with aspirin (Percodan)
- Oxymorphone (Opana)
The agreement of 6 January 2006 for Endo Pharmaceuticals to market Synera (lidocaine plus tetracaine patch) was terminated on 31 July 2008. Endo is no longer involved with the Synera patch. Zars Pharmaceuticals is the patent holder for Synera. The rights to Synera passed to Nuvo Research of Canada in May, 2011 upon the acquisition of ZARS Pharmaceuticals by Nuvo Research.
See also 
- "Endo | Press Releases". endo.com. 2012 [last update]. Retrieved May 23, 2012.
- Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28.
- Staff (2006-12-06). "Endo Health Solutions Inc.". Delaware News Journal. Retrieved 2006-12-06.[dead link]
- "Product Listing". Endo Pharmaceuticals. 2006. Retrieved 2006-12-06.
- "Corporate Officers". Endo Pharmaceuticals. 2008. Retrieved 2008-09-15.
|This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it.|